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Abstract 
As the Covid-19 pandemic escalates worldwide it is apparent that many patients 
with more severe illness will also experience delirium. These patients pose a 
particular challenge in the application of optimal care due to issues with infectious 
risk, respiratory compromise and potential interactions between medications that 
can be used to manage delirium with antiviral and other treatments used for 
Covid-19. We describe a guidance resource adapted from existing guidelines for 
delirium management that has been tailored to the specific challenge of managing 
delirium in patients with Covid-19 infection. Issues around the assessment and 
treatment of these patients are examined and distilled into a simple (one-paged 
guidance resource that can assist clinicians in managing suspected delirium. 
Background 
The healthcare community is currently in the grip of a pandemic due to COVID-19 
(coronavirus SARS-CoV-2) (Zhou et al, 2020), with growing worldwide mortality 
especially amongst elderly and those with pre-existing comorbidities such as 
cardiorespiratory disease, diabetes and dementia. In addition to fever and 
respiratory symptoms, a substantial number of patients experience neurological 
difficulties, with reports of ‘impaired consciousness’ in 15% of those with severe 
illness in one series (Mao et al, 2020) and ‘confusion’ reported in 9% at 
presentation in another (Chen et al, 2020; Meo et al, 2020).  
Against this backdrop it can be expected that delirium will complicate illness 
course in many patients with Covid-19. Moreover, the management of delirium in 
these patients is especially challenging as the application of many non-
pharmacological strategies to manage delirium is curtailed by the need to minimise 
infectious risk (LaHue et al, 2020), while medications used in delirium 
management have recognised capacity to cause respiratory depression and have 
interactions with antiviral and other agents used to treat Covid-19.  
As a result, existing guidelines on delirium management need to be carefully 
considered and adapted to the needs of patients with Covid-19. From an Irish 
perspective, clinicians from the Department of Psychiatry at University Hospital 
Limerick have with psychiatry and geriatric medicine clinicians that have particular 
interest in the management of delirium to develop a user-friendly and practical 
guidance document that is tailored to the particular challenge of suspected 
delirium in patients with Covid-19. In this paper we describe the development of 
this resource and examine emerging literature that addresses key considerations 
relevant to the provision of optimal care to patients with Covid-19 who experience 
delirium.   
Existing resources  
The management of delirium in everyday clinical practice is typically guided by a 
variety of existing resources that include formal guidelines (e.g. National Institute 
for Health and Clinical Excellence, 2010; Scottish Intercollegiate Guidelines 
Network, 2019), as well as various guidance material developed by local 
departments (e.g. Policy for management of suspected delirium Psychiatry for 
later Life service, University Hospital Limerick) as well as by National groups (e.g. 
Health Services Executive: Early identification and management of delirium in the 
emergency department and acute medical assessment unit). These resources 
address many important aspects of delirium as it relates to the legion of possible 
causes that occur in everyday clinical practice including detection and diagnosis, 
investigation for underlying causes, non-pharmacological management and advice 
regarding the circumstances under which pharmacological interventions can be 
applied, including choice of agent, dosing and monitoring of response and adverse 
effects.  
Additional guidance resources 
In response to the Covid pandemic, a variety of position statements and guidance 
resources documents have emerged to supplement these existing resources by 
addressing the specific challenges posed by patients with Covid-19 in terms of 
minimising infectious risk through efficient recognition of delirium, prudent 
application of environmental and other non-pharmacological efforts to minimise 
the occurrence and impact of delirium in Covid-19 patients, and the key 
considerations around use of pharmacological interventions, including their 
rationale, interactions with other medications that may be used in these patients, 
and potential for adverse effects (British Geriatrics Society, European Delirium 
Association, Old Age Psychiatry Faculty of the Royal College of Psychiatrists, 2020; 
Gee and Taylor, 2020; Liverpool Drug Interactions Group). 
Detection 
A number of issues particular to delirium assessment in patients with Covid-19 are 
evident. Firstly, delirium detection must be sensitive to the need for rapid and 
efficient assessment that minimises the duration of interactions that can be 
physically and mentally demanding on highly morbid patients. The 4AT is a 
practical and simple tool for the efficient assessment of possible delirium that is 
brief (requires less than 2 minutes), has excellent patient coverage (i.e. allows 
assessment of patients with severe drowsiness or agitation who are less able to 
communicate), and does not require any special training. It is supported by at least 
11 validation studies (involving >2500 patients) that indicate high sensitivity (83-
100%) with moderate to high specificity (70-99%) for delirium (see www.4AT.com) 
(Shenkin et al, 2019). For these reasons, the 4AT has become the preferred tool 
that is recommended for delirium detection by recent guidelines and is suited to 
the challenges of Covid-19 as it is brief, minimally demanding upon patients and 
does not include any elements (e.g. pen and paper) that require physical contact. 
It is important to note that where a patient is unable to engage with testing (e.g. 
the months backwards test) this is considered a failed performance and scored 
accordingly. This reduces the likelihood of patients with severe delirium being 
missed.   
Non-pharmacological management 
Early reports from the Italian experience of the Covid-19 pandemic (di Giacomo et 
al, 2020) have highlighted how providing a delirium-friendly care environment is 
extremely challenging for many patients with Covid-19 as for many the experience 
of being nursed in isolation by staff using PPE may create an anxiogenic and 
threatening care environment. In addition, many of the principles of routine 
management of the care environment may not be realistic such as consistency of 
staffing, facilitated mobilisation, providing bedside sitters, and involving family in 
care provision. However, many of the other elements to good care of those at risk 
of delirium continue to apply such as optimising sensory abilities, clear and concise 
communication and careful attention to medication regimes to minimise use of 
deliriogenic medications and polypharmacy. In addition, in many centres staff have 
identified creative ways of reducing the impersonal nature of providing care when 
using PPE such as wearing large named identification photographs when engaging 
with patients receiving care in isolation.  
Outbreaks of COVID-19 have become common in residential care settings in 
Ireland, as elsewhere and in many cases delirium can be the principal presenting 
feature. Many such residents are frail, and some are approaching the end of life. It 
is usually appropriate to manage such residents in the nursing home, often with 
palliative care measures, unless it is judged that transfer an acute hospital may 
provide clinical benefit. This presents a challenging risk-benefit analysis that 
requires careful consideration of baseline functioning and the likely benefits of 
more intense supportive intervention versus the recognised  risk of provoking or 
exacerbating delirium already delirium-prone persons. The detection and 
management strategies outlined in this paper can also be applied in nursing home 
settings, with adaptation according to the resources that are available in each 
setting.   
Assessing causation 
Delirium can be secondary to insults located within the CNS but also commonly 
occurs in response to disturbances that are primarily located systemically, such as 
peripheral infection, organ failure or metabolic disruptions. The precise 
mechanisms by which Covid-19 may cause neurological manifestations are still 
unclear but may include direct CNS infection, access due to reduced blood-brain 
barrier integrity, retrograde neuronal transport, hypoxic damage, vascular 
mechanisms and neuroinflammatory responses, along with the many other causes 
that have been  associated with increased delirium propensity. In addition, 
patients in isolation, requiring mechanical ventilation, with reduced sensory input 
and mobilisation are all more prone to developing delirium (Kotfis et al, 2020).   
In addressing delirium it is always important to recognise that it is a multifactorial 
condition, typically with more than one causative factor and that a variety of 
factors can serve as precipitating and/or aggravating issues. The primary aim of 
delirium treatment is to address the etiological cause(s). The PINCH-ME algorithm 
(see figure 1) is frequently used to guide etiological assessment and is applicable 
to patients with Covid-19.  
Management of agitated and distressed patients with delirium 
In addition, the delirious state can be highly problematic in terms of patient 
distress and behavioural disturbance. The use of antipsychotic agents in the 
management of delirium is the source of ongoing debate with the current 
consensus that these agents are not a treatment for delirium per se (Burry et al, 
2018; Nikooie et al, 2019) but can be used to manage symptoms of delirium where 
the balance of risk in terms of potential adverse effects allows (Meagher et al, 
2018). Although the demographic pattern of older patients being prone to 
experiencing more severe illness with Covid-19 suggests that hypoactive 
presentations will be prominent (Meagher, 2009), a substantial minority will 
experience hyperactivity that impacts upon patient wellbeing in terms of 
distressing psychotic and affective disturbances, risk of falls and other injuries, 
ability to receive optimal care and elevated infectious risk. It may be expected 
that with reduced capacity to provide non-pharmacological supports, medications 
will need to be considered in a substantial percentage of these patients. However, 
these decisions are further complicated by heightened vulnerability to adverse 
effects from pharmacological treatments. In addition to the usual concerns about 
toxicity in terms of extrapyramidal effects, cardiotoxicity and cerebrovascular 
effects, patients with Covid-19 can be expected to be more vulnerable to 
respiratory depression and cardiac effects.  
Benzodiazepines 
Although there is no evidence to support the use of benzodiazepines in the 
treatment of delirium among hospitalised patients except in alcohol or 
benzodiazepine withdrawal (Lonergan et al, 2009) or in palliative care (Finucane et 
al 2020), they are still in use despite their documented capacity to cause or 
worsen delirium. Both antipsychotic agents and benzodiazepines have potential to 
cause respiratory depression, but this is particularly significant with 
benzodiazepines which are associated with dose-related centrally mediated 
respiratory depression (Ekstrom et al, 2014; Vozoris, 2014) and, as such, 
benzodiazepines should only be used with great caution in patients with 
respiratory compromise (Shah et al, 2017; Fraser et al 2013). In summary, 
benzodiazepine use should be avoided for treating delirium in Covid-19 infected 
patients (LaHue et al, 2020) or should be limited to patients who cannot tolerate 
antipsychotics or who have other contraindications to their use (e.g. Parkinson’s 
disease or Lewy Body Dementia) or have withdrawal or seizure-related symptoms. 
Where benzodiazepines are used this should include careful monitoring of effects 
and an awareness that their respiratory effects can be reversed with flumazenil. It 
must equally be highlighted that benzodiazepines are perfectly appropriate as a 
palliative treatment for severe respiratory distress, including end-of-life care, and 
indeed have an important role here in palliation and reducing anxiety. This 
indication is clearly differentiated from their use specifically to treat delirium 




As such, where pharmacological treatment is required to counter the challenge of 
distressing psychosis and /or otherwise unmanageable behavioural disturbance, 
antipsychotic agents are considered the first choice intervention. Existing 
guidelines varying in suggested agents of first choice, with haloperidol, olanzapine, 
risperidone and quetiapine recommended as possible treatments. However, in the 
context of Covid-19, cardiac effects, particularly when used in combination with 
antiviral agents, are an important concern and evidence suggests that olanzapine 
has a favourable profile compared to risperidone and quetiapine (see below), while 
haloperidol remains a useful option due to the range of routes by which it can be 
administered (see table 1 below).  
 
Where antipsychotic agents are used, it is important to monitor cardiac function 
and in particular to rule out QT prolongation with a baseline ECG. Moreover, use of 
antipsychotics brings with it a risk of a variety of other potential adverse effects, 
with a significantly increased risk of cerebrovascular incidents especially in 
patients with pre-existing cognitive issues such as dementia (Rao et al, 2016), as 
well as extrapyramidal and anticholinergic effects (e.g. cardiac conduction effects 
and increased hyperpyrexia risk), with the latter more commonly attributed to 
olanzapine than other second generation antipsychotics (Gardner et al, 2005). Of 
note, the evidence suggests that extrapyramidal effects are uncommon with low 
dose use (Burry et al, 2018). Other evidence suggests that cardiac effects are rare 
where cumulative daily doses of intravenous haloperidol are lower than 2 mg, 
unless patients have additional risk factors for QTc prolongation (Meyer-Massetti et 
al., 2010). Suggested doses are shown in figure 1 with the usual rule of ‘start low 
and go slow’ particularly important given the age profile and level of morbidity of 
many patients with symptomatic Covid-19. In addition, patients experiencing 
hyperinflammatory states can have increased brain permeability to neurotoxins 
that in turn can confer greater sensitivity to adverse effects from psychotropic 
agents (Wu et al, 2020).       
Potential interactions between psychotropic and antiviral agents 
A further consideration relates to potential interactions between psychotropic 
agents and other treatments used in these patients, with antiviral agents a 
particular focus of concern. The Liverpool Drug Interaction Group (based at the 
University of Liverpool, UK), in collaboration with the University Hospital of Basel 
(Switzerland) and Radboud UMC (Netherlands), have collated information regarding 
interactions between over 400 medications (including psychotropics) and 
experimental COVID-19 therapies (e.g. atazanavir, lopinavir/ritonavir, remdesivir, 
favipiravir, chloroquine, hydroxychloroquine, ribavirin, tocilizumab, interferon 
beta)(see www.covid19-druginteractions.org). This information indicates a 
favourable profile for olanzapine in terms of interactions with antiviral agents, 
while haloperidol, risperidone and quetiapine increase the exposure to potential 
adverse effects of many antiviral agents and haloperidol warrants particular 
caution in respect of potential for effects on cardiac conduction.  
A guidance resource for managing delirium in Covid-19 patients 
Taking all of these considerations into account, we have composed a guidance 
sheet that can assist non-expert clinicians in how to manage Covid-19 patients that 
have suspected delirium. It is brief (occupying one side of a page) and practical, 
addressing four steps in decision-making (1) assessment for delirium using the 4AT, 
(2) assessing potential etiological factors using the PINCH-ME algorithm, (3) 
guidance on non-pharmacological management, and finally, (4) guidance on use of 
pharmacological interventions. While in many cases, clinicians will be comfortable 
in detecting and managing delirium, this guidance can assist where a more 
structured approach is needed. It can also serve as a useful support to guide 
efforts to assess and manage delirium in consultation with psychiatry services. This 
guidance provides a rapid response to the need to focus our efforts to manage 
delirium during the pandemic that has been disseminated to support everyday 
practice in local services and beyond. It can also provide a document that can be 
further developed in a more systematic way (e.g. consensus guidelines) over time 
as further evidence (e.g. around existing or additional treatments for Covid-19) 
emerges. 
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Table 1. Drug interactions between commonly used medications in delirium and 
Covid-19 agents (adapted from Liverpool Drug Interactions Group). 
 ATZ LPRT REM FAV CHL NIT RIB TOC 
Haloperidol ↑♥ ↑♥ ↔ ↔ ↔♥ ↔ ↔ ↔ 
Olanzapine ↔ ↓ ↔ ↔ ↔ ↔ ↔ ↔ 
Risperidone ↑♥ ↑♥ ↔ ↔ ↑♥ ↔ ↔ ↔ 
Quetiapine ↑♥ ↑♥ ↔ ↔ ↔♥ ↔ ↔ ↔ 
Diazepam ↑ ↑ ↔ ↔ ↔ ↔ ↔ ↔ 
Lorazepam ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ 
Midazolam ↑ ↑ ↔ ↔ ↔ ↔ ↔ ↔ 
ATZ: Atazanavir, LPRT: Lopinavir/Ritonavir, REM: Remdesivir, FAV: Favipiravir, 
CHL: Chloroquine/Hydroxychloroquine, NIT: Nitazonide, RIB: Ribavirin, TOC: 
Tocilizumab. 
↑: Potential for increased medication effects / ↓; Potential for decreased 
medication effects 














Figure 1. Management Tips for Suspected Delirium in patients with Covid-19.  
 
